UK – AZ to appeal NICE rejection for lung cancer drug

AstraZeneca has announced plans to appeal the The National Institute for Health and Care Excellence’s (NICE) decision to reject its non-small cell lung cancer (NSCLC) drug, Tagrisso (osimertinib).

The committee didn’t OK the drug as the cost effectiveness estimates were above what NICE normally considers to be an acceptable use of NHS resources. AstraZeneca, however, believes that the treatment would be considered a cost-effective use of the NHS resources if it was granted End of Life status, which is a status given to medicines for patients who have a short life expectancy, typically less than 24 months.

The indication was for untreated locally advances or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) in adults.

The company’s CEO, Pascal Soriot, said that they are “Very disappointed with this decision and will appeal. The UK has the second worst lung cancer survival outcomes in Europe and patients need new innovative treatments…